Drug resistance mutations in polymerase region and related influencing factors in patients with hepatitis B virus infection

Li Sha; Peng HuaBin; Li ShuQin; Zhou Jing; Wang LiPing

doi:10.3969/j.issn.1001-5256.2020.06.012

Volume 36 Issue 6

Jun. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(6): 1245-1251

PDF( 2079 KB)

Drug resistance mutations in polymerase region and related influencing factors in patients with hepatitis B virus infection

DOI: 10.3969/j.issn.1001-5256.2020.06.012

Research funding:

Published Date: 2020-06-20

Abstract

Abstract

Objective To investigate the pattern of drug resistance mutations of the genes in the reverse transcriptase( RT) region and its association with clinical features in patients with hepatitis B virus( HBV) infection in Xuzhou,Jiangsu,China,as well as the influencing factors for drug resistance. Methods A total of 242 patients with HBV infection who underwent the detection of the HBV RT region in Department of Infectious Diseases,The Affiliated Hospital of Xuzhou Medical University,from May 2014 to April 2019 were enrolled,and the clinical features were compared between the patients with different genotypes and HBeAg statuses. Of all patients,164 had a clear medication history of nucleos( t) ide analogues( NAs),among whom 118 had known mutations at drug resistance loci and 46 did not have such mutations,and the risk factors for drug resistance mutations in the HBV RT region were analyzed for the two groups. The independent samples t-test or the Mann-Whitney U test was used for comparison of continuous data between groups; the chi-square test was used for comparison of categorical data between groups; a logistic regression analysis was used to investigate the risk factors for drug resistance. Results Among the patients with HBV infection in Xuzhou,rtL180 M + rtM204 I/V/S was the most common pattern of drug resistance mutation in the RT region and was observed in 25 patients( 21. 2%),followed by rtA181 T/V in 16 patients( 13. 6%) and rtM204 I/V/S in 15 patients( 12. 7%). Of all 242 patients,13( 5. 4%) had genotype B and 229( 94. 6%) had genotype C,and no other genotypes were found. The patients with genotype B had a significantly higher level of alanine aminotransferase( ALT) than those with genotype C( U =-2. 096,P =0. 036). Compared with the HBeAg-positive group,the HBeAg-negative group had a significantly older age( t = 4. 580,P < 0. 001) and significantly lower HBV DNA load and HBs Ag level( t = 2. 145 and 3. 526,P = 0. 033 and 0. 001). The HBe Ag-negative group had a significantly longer course of disease and a significantly higher level of gamma-glutamyl transpeptidase( GGT) than the HBe Ag-positive group( U =-2. 561 and-2. 016,P = 0. 010 and 0. 044). Compared with the HBe Ag-positive group,the HBe Ag-negative group had a significantly lower proportion of patients with chronic hepatitis B and a significantly higher proportion of patients with liver cirrhosis or hepatocellular carcinoma( χ2= 20. 609,P < 0. 001). The multivariate logistic regression analysis showed that administration of lamivudine + adefovir dipivoxil( OR = 0. 080,95% CI: 0. 008-0. 748,P < 0. 05),administration of adefovir dipivoxil( OR = 5. 493,95% CI: 1. 377-21. 909,P < 0. 05),and improper drug withdrawal( OR = 5. 945,95% CI: 1. 921-18. 403,P < 0. 05) were independent risk factors for drug resistance in patients with HBV infection. Conclusion Most of the patients with HBV infection in Xuzhou are infected with HBV genotype C,with a complex and diverse pattern of drug resistance mutations. HBV DNA replication is active in HBe Ag-positive patients,and therefore,it is recommended to initially select antiviral drugs with high efficiency and low resistance and strengthen the compliance with antiviral therapy.
- hepatitis B virus,
- mutation antiviral agents,
- nucleoside(acid) analogues,

FullText(HTML)

References(24)

References

[1] CALIGIURI P,CERRUTI R,ICARDI G,et al. Overview of hepatitis B virus mutations and their implications in the management of infection[J]. World J Gastroenterol,2016,22(1):145-154.

[2] SONG JE,LEE CH,KIM BS. Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice[J]. Korean J Intern Med,2019,34(4):802-810.

[3] Chinese Society of Infectious Disease,Chinese Medical Association; Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol,2019,35(12):2648-2669.(in Chinese)中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎防治指南(2019年版)[J]．临床肝胆病杂志，2019,35(12):2648-2669.

[4] MANTOVANI N,CICERO M,SANTANA LC,et al. Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and So Paulo,Brazil[J]. Virol J,2013,10:320.

[5] ORLANDO R,TOSONE G,PORTELLA G,et al. Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBs Ag-positive chronic hepatitis patient:A case report[J]. Infection,2008,36(5):472-474.

[6] Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1941-1960.

[7] JIANG M,GONG X,XIAO XQ,et al. Expression of serum miRNA-122-3p in patients with CHB treated with PEG-interferon-alpha 2b[J]. Int J Virol,2019,26(5):293-298.(in Chinese)蒋敏，龚兴，肖新强，等．血清miRNA-122-3p在聚乙二醇干扰素-α2b治疗CHB患者中表达的研究[J]．国际病毒学杂志，2019,26(5):293-298.

[8] ZHANG HY,LIU LG,YE CY,et al. Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years(2010-2016)[J]. Virus Genes,2018,54(1):41-47.

[9] QIAN F,QIN J,LI D,et al. Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou,China[J]. J Infect Dev Ctries,2016,10(9):996-1002.

[10] Experts Attending the Disscussion on Hepatitis B Virus Drug Resistance. Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management[J]. J ClinHepatol,2013,29(1):10-17.(in Chinese)参加乙型肝炎耐药讨论会专家．核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J]．临床肝胆病杂志，2013,29(1):10-17.

[11] LIU Y,ZHOU Y,LI X,et al. Hepatitis B virus mutation pattern rt L180M+A181C+M204V may contribute to entecavir resistance in clinical practice[J]. Emerg Microbes Infect,2019,8(1):354-365.

[12] LEE CI,KWON SY,KIM JH,et al. Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure[J]. Gut Liver,2014,8(1):64-69.

[13] SVAROVSKAIA ES,CURTIS M,ZHU Y,et al. Hepatitis B virus wild-type and rt N236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovirbased regimen[J]. J Viral Hepat,2013,20(2):131-140.

[14] YEH CT,CHEN T,HSU CW,et al. Emergence of the rt A181T/s W172*mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B[J]. BMC Cancer,2011,11:398.

[15] TERRAULT NA,LOK A,MCMAHON BJ,et al. Update on prevention,diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599.

[16] European Association for the Study of the Liver,European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol,2017,67(2):370-398.

[17] LIVINGSTON SE,SIMONETTI JP,MCMAHON BJ,et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma:Preponderance of genotype F[J]. J Infect Dis,2007,195(1):5-11.

[18] WANG LP,CHENG X,LI CY,et al. Relationship between pre-existing resistance mutations and HBV genotype in patients with HBV related liver cirrhosis[J]. World Chin J Dig,2017,25(10):891-896.(in Chinese)汪莉萍，程笑，李春杨，等．乙型肝炎肝硬化患者HBV预存耐药变异与基因型的关系[J]．世界华人消化杂志，2017,25(10):891-896.

[19] BAO T,HU QG,YE J,et al. Value of HBs Ag level in dynamic monitoring of disease progression in patients with chronic HBV infection[J]. J Clin Hepatol,2017,33(8):1475-1478.(in Chinese)鲍腾，胡庆刚，叶珺，等．HBsAg水平在慢性HBV感染者疾病进展中的动态监测价值[J]．临床肝胆病杂志，2017,33(8):1475-1478.

[20] HU GF,LI XP,WU ZP,et al. Clinical features of acute-onchronic liver failure induced by withdrawl of nucleos(t)ide analogues[J]. J Clin Hepatol,2017,33(7):1320-1323.(in Chinese)胡高飞，李小鹏，吴振平，等．停用核苷和核苷酸类药物抗HBV后诱发慢加急性肝衰竭的临床特征[J]．临床肝胆病杂志，2017,33(7):1320-1323.

[21] HA NB,HA NB,GARCIA RT,et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B[J]. Dig Dis Sci,2011,56(8):2423-2431.

[22] LEE HW,PARK JY,LEE JW,et al. Long-term efficacy of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic HBV infection[J]. Clin Gastroenterol Hepatol,2019,17(7):1348-1355. e2.

[23] LIM YS,GWAK GY,CHOI J,et al. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B:A 5-year clinical trial[J]. J Hepatol,2019,71(1):35-44.

[24] SHIRVANI-DASTGERDI E,WINER BY,CELI-TERRASSA T,et al. Selection of the highly replicative and partially multidrug resistant rt S78T HBV polymerase mutation during TDF-ETV combination therapy[J]. J Hepatol,2017,67(2):246-254.

Relative Articles

[1]	Xiumin CHEN, Shenglong LIN, Xiangmei WANG, Huaxi MA, Dongqing ZHANG, Ziyuan LIAO, Minghua LIN, Haibing GAO. Association of energy metabolic markers with the short-term risk of spontaneous bacterial peritonitis in patients with decompensated hepatitis B virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(6): 1311-1316. doi: 10.3969/j.issn.1001-5256.2022.06.018
[2]	Jin GUO, Chunxia SHI, Wei DENG, Qian CHEN, Zuojiong GONG. Research advances in the features of nutrition metabolism and nutritional support in liver failure[J]. Journal of Clinical Hepatology, 2022, 38(3): 703-707. doi: 10.3969/j.issn.1001-5256.2022.03.043
[3]	LV SuCong, ZHANG BaoZhong. Etiology,clinical manifestations,and prognosis of liver failure in pregnancy[J]. Journal of Clinical Hepatology, 2020, 36(12): 2756-2760. doi: 10.3969/j.issn.1001-5256.2020.12.023
[4]	LI Hui, WANG YongGang, SU HaiBin. Application of blood lactate level in evaluating the prognosis of liver failure patients[J]. Journal of Clinical Hepatology, 2020, 36(11): 2609-2612. doi: 10.3969/j.issn.1001-5256.2020.11.048
[5]	Zhang BaoZhong, Zhou PengZhi. Influencing factors for short-term prognosis of liver failure in pregnancy[J]. Journal of Clinical Hepatology, 2019, 35(2): 414-418. doi: 10.3969/j.issn.1001-5256.2019.02.040
[6]	Liu YeYing, Wang Ting, Dou AiHua, Zheng SuJun, Xu Bin, Liu Mei. Current status and perspectives of prognostic markers for liver failure[J]. Journal of Clinical Hepatology, 2019, 35(5): 1135-1139. doi: 10.3969/j.issn.1001-5256.2019.05.046
[7]	Zhang DongJing, Zhou Bin, Hou JinLin. Research progress in prognostic models of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2018, 34(6): 1351-1356. doi: 10.3969/j.issn.1001-5256.2018.06.047
[8]	Han PuQing, Sun Yan. Prognostic models for liver failure and their role in pregnant women with liver failure[J]. Journal of Clinical Hepatology, 2018, 34(3): 635-640. doi: 10.3969/j.issn.1001-5256.2018.03.044
[9]	Li Ying, Zhan Jing, Wang ZhongFeng. Prognostic factors for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2017, 33(3): 497-501. doi: 10.3969/j.issn.1001-5256.2017.03.020
[10]	Lin Feng. Research advances in clinical diagnosis,prognostic evaluation,and treatment of liver failure[J]. Journal of Clinical Hepatology, 2016, 32(9): 1678-1683. doi: 10.3969/j.issn.1001-5256.2016.09.009
[11]	Zhang Jing, Zhou XinMin. Disease assessment and prognosis of liver failure[J]. Journal of Clinical Hepatology, 2016, 32(9): 1673-1677. doi: 10.3969/j.issn.1001-5256.2016.09.008
[12]	Han Tao, Zhang YuLing. Predictive and prognostic evaluation of hepatitis B virus-induced liver failure[J]. Journal of Clinical Hepatology, 2015, 31(4): 505-509. doi: 10.3969/j.issn.1001-5256.2015.04.007
[13]	Tang ShanHong, Zeng WeiZheng, Jiang MingDe, Fan QuanShui. Research progress in prediction of clinical outcome in patients with liver failure[J]. Journal of Clinical Hepatology, 2015, 31(1): 135-138. doi: 10.3969/j.issn.1001-5256.2015.01.031
[14]	Zhao Juan, Liu YaZhou, Dai Lu, Wang JinHuan, Li Juan, Yu HongWei, Meng QingHua. Characteristics of energy metabolism in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2015, 31(5): 716-720. doi: 10.3969/j.issn.1001-5256.2015.05.020
[15]	Li XinYan, Huang ShuLin, Fang Liang, Lei RuiXiang, Ke WeiMin. A simple scoring system for evaluating severity of HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2014, 30(10): 996-999. doi: 10.3969/j.issn.1001-5256.2014.10.006
[16]	Zhang YuLing, Han Tao, Zhang Min, Zhang Qian. Research progress in prognostic markers of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2014, 30(10): 1078-1081. doi: 10.3969/j.issn.1001-5256.2014.10.026
[17]	Liu JieYu, Feng YiChao. Analysis of prognostic models for liver failure [J]. Journal of Clinical Hepatology, 2014, 30(10): 1082-1086. doi: 10.3969/j.issn.1001-5256.2014.10.027
[18]	Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
[19]	Zhang WenHua, Jia WenLing, Zhou ZiYing, Tang HaiTao, Wang FengMei. Investigation on the method and safety of the non-heparinized plasma exchange therapy in treating patients with hepatic failure[J]. Journal of Clinical Hepatology, 2012, 28(1): 50-52.
[20]	Yang Bo, Wu YuanKai, Chen ZhongCheng, Gao ZhiLiang, Chong YuTian, Xie ShiBin. The dynamic changes of AST, ALT, TBil and PT and their relationship with prognosis of acute-on-chronic hepatitis B liver failure[J]. Journal of Clinical Hepatology, 2012, 28(3): 205-208.

Supplements(0)

Cited By

Cited by

Periodical cited type(1)

穆亚娟，高晓霞，王蒙，贺亚妮. 维生素D3辅助阿德福韦酯及拉米夫定治疗乙型肝炎肝硬化对患者肝纤维化指标、细胞免疫的影响. 中国基层医药. 2024(06): 858-862 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1212) PDF downloads(172)

Drug resistance mutations in polymerase region and related influencing factors in patients with hepatitis B virus infection

DOI: 10.3969/j.issn.1001-5256.2020.06.012